Form 8-K
8-K — Dermata Therapeutics, Inc.
Accession: 0001493152-26-037124
Filed: 2026-08-11
Period: 2026-08-11
CIK: 0001853816
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001853816
0001853816
2026-08-11
2026-08-11
0001853816
DRMA:CommonStockParValue0.0001PerShareMember
2026-08-11
2026-08-11
0001853816
DRMA:WarrantsExercisableForOneShareOfCommonStockMember
2026-08-11
2026-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 11, 2026
DERMATA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-40739
86-3218736
(State
or other jurisdiction
(Commission
(IRS
Employer
of
incorporation)
File
Number)
Identification
No.)
3525
Del Mar Heights Rd., #322
San
Diego, CA
92130
(Address
of principal executive offices)
(Zip
Code)
(858)
800-2543
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of exchange on which registered
Common
Stock, par value $0.0001 per share
DRMA
The
Nasdaq Capital Market
Warrants,
exercisable for one share of Common Stock
DRMAW
The
Nasdaq Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
2.02. Results of Operation and Financial Condition.
On
August 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding
its results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished
under Item 2.02 as Exhibit 99.1.
The
information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”
for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange
Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange
Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such
filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
99.1
Press Release, dated August 11, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026”
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document).
-2-
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
DERMATA
THERAPEUTICS, INC.
Dated:
August 11, 2026
By:
/s/
Gerald T. Proehl
Name:
Gerald
T. Proehl
Title:
President,
Chairman and Chief Executive Officer
-3-
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit
99.1
Dermata
Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
-
Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026
–
-
Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -
SAN
DIEGO, CA, August 11, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”),
a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the
second quarter ended June 30, 2026.
“Over
the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,”
commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution
across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect
to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped
‘white space’ to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues
in the near future while continuing to build long-term value for our shareholders,” continued Mr. Proehl. “Looking ahead,
we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the
foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement,
and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated
skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to
come,” concluded Mr. Proehl.
Corporate
Highlights
● Attended
first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand.
In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially
launch the Tome brand and provided attendees with more information on the upcoming launch
of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa,
and wellness professionals with over 400+ brands in attendance.
● Began
social media campaign for its new skincare brand, Tome. The Company recently unveiled
the Tome brand’s official social media presence as part of the Company’s broader
commercial launch strategy. These efforts are designed to increase brand awareness, engage
prospective consumers, and support the successful ecommerce launch of the Company’s
first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.
Anticipated
Upcoming Milestones
● Launch
first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on
August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational
Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome
Foundational Treatment can be the base of any skincare routine, designed to renew the appearance
of the skin and simplify skincare with a once-weekly application.
● Continue
development of a second DTC product. The Company is also working on its second skincare
product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected
to launch sometime after its Foundational Treatment.
Second
Quarter 2026 Financial Results
As
of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1
million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations,
and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects
its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.
Research
and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30,
2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company’s decision to prioritize
the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended
June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company
reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development
expenses will continue to decrease compared to prior periods.
Selling,
general and administrative expenses were $2.8 million for the quarter ended June 30, 2026, compared to $1.2 million for the quarter ended
June 30, 2025. The increase in selling, general and administrative expenses was primarily attributable to $0.7 million of increased legal
fees, an increase of $0.6 million of marketing and other commercialization expenses, and an increase of $0.3 million of employee compensation
attributable to a reallocation of employee efforts from research and development activities toward pre-commercial activities in anticipation
of the Company’s first product launch.
About
Dermata Therapeutics
Dermata
Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development
to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing
a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first
product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more
information, or to join our mailing list, please visit http://www.dermatarx.com/.
About
Tome
Tome
is Dermata’s new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal
meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in
science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris,
a wild harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are compelled
by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify
existing skincare routines with essential ingredients that deliver results, without the recovery associated with in-office treatments.
Dermata expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with additional product launches planned
to follow. Start your skincare story at www.tomeskincare.com.
Forward-Looking
Statements
Statements
in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s
current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to
prioritize DTC and OTC skincare products; the anticipated benefits of Dermata’s strategic shift to prioritize DTC and OTC skincare
products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer
markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Foundational Treatment;
the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company’s
products and their ability to generate revenue for the Company; the Company’s expectations with regard to current cash and cash
equivalents and the amount of time it will fund operations; and other factors described in the Company’s filings with the Securities
and Exchange Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,”
“should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,”
“expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential”
and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in
any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization.
For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified
in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect
events or circumstances after the date hereof, except as required by law.
DERMATA
THERAPEUTICS, INC.
Balance
Sheets
In thousands USD
June 30, 2026
December 31, 2025
(unaudited)
Assets
Cash and cash equivalents
$ 4,413
$ 7,522
Prepaid expenses and other current assets
594
342
Inventories
150
-
Non-current assets
164
-
Total assets
5,321
7,864
Liabilities
Accounts payable
1,120
461
Accrued liabilities
713
1,180
Total liabilities
1,833
1,641
Equity
3,488
6,223
Total liabilities and equity
$ 5,321
$ 7,864
DERMATA
THERAPEUTICS, INC.
Statements
of Operations
(unaudited)
Quarter Ended June 30,
Six Months Ended June 30,
In thousands, except share and per share data
2026
2025
2026
2025
Operating expenses
Research and development (1)
$ 213
$ 618
$ 596
$ 1,899
Selling, general and administrative (1)
2,801
1,155
4,344
2,214
Total operating expenses
3,014
1,773
4,940
4,113
Loss from operations
(3,014 )
(1,773 )
(4,940 )
(4,113 )
Interest income
47
72
125
108
Net loss
$ (2,967 )
$ (1,701 )
$ (4,815 )
$ (4,005 )
Net loss per common share, basic and diluted
$ (0.74 )
$ (1.66 )
$ (1.22 )
$ (5.18 )
Weighted average common shares outstanding, basic and diluted
4,022,143
1,026,506
3,940,983
772,397
(1) Includes the following stock-based compensation expense
Research and development
$ 4
$ 8
$ 18
$ 16
Selling, general and administrative
$ 38
$ 31
$ 67
$ 61
Investor
Contact:
Cliff
Mastricola
Investor
Relations
cmastricola@dermatarx.com
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 3
Binary file (4168 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Cover
Aug. 11, 2026
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 11, 2026
Entity File Number
001-40739
Entity Registrant Name
DERMATA
THERAPEUTICS, INC.
Entity Central Index Key
0001853816
Entity Tax Identification Number
86-3218736
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
3525
Del Mar Heights Rd.
Entity Address, Address Line Two
#322
Entity Address, City or Town
San
Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92130
City Area Code
(858)
Local Phone Number
800-2543
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
true
Common Stock, par value $0.0001 per share
Title of 12(b) Security
Common
Stock, par value $0.0001 per share
Trading Symbol
DRMA
Security Exchange Name
NASDAQ
Warrants, exercisable for one share of Common Stock
Title of 12(b) Security
Warrants,
exercisable for one share of Common Stock
Trading Symbol
DRMAW
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=DRMA_CommonStockParValue0.0001PerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=DRMA_WarrantsExercisableForOneShareOfCommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: